Literature DB >> 20973706

Time course and predictors of health-related quality of life improvement and medication satisfaction in children diagnosed with attention-deficit/hyperactivity disorder treated with the methylphenidate transdermal system.

Thomas W Frazier1, Margaret Weiss, Paul Hodgkins, Michael J Manos, Jeanne M Landgraf, Christopher Gibbins.   

Abstract

OBJECTIVE: The aim of this study was to evaluate the time course and predictors of improvement in health-related quality of life (HRQL) and medication satisfaction in children diagnosed with attention-deficit/hyperactivity disorder (ADHD) and treated with the methylphenidate transdermal system (MTS).
METHODS: Temporal relationships between ADHD symptoms, medication satisfaction, and HRQL measures were examined via latent growth curve, structural path, and growth mixture models.
RESULTS: Higher levels of medication satisfaction at the end of titration predicted greater increases in family HRQL (p=0.004) and, to a lesser extent, child HRQL (p=0.068) throughout the study. At 4 of 6 (p<0.05) and 5 of 6 (p<0.10) contemporaneous time points, ADHD symptoms predicted child HRQL. At 2 of 6 (p<0.05) and 3 of 6 (p<0.10) contemporaneous time points, ADHD symptoms predicted family HRQL. ADHD did not predict child or family HRQL improvements at subsequent time points. A uniform pattern of change for child HRQL was noted, with most HRQL change following the pattern of symptom change during titration. Three distinct patterns of change were noted for family HRQL.
CONCLUSIONS: In most cases, medication satisfaction, ADHD symptoms, and HRQL improved simultaneously, suggesting that HRQL was not a delayed response to improvement in symptoms. Children showed a uniform pattern of improvement in HRQL that followed symptom change; three distinct patterns of change were found for improvement in family HRQL.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20973706     DOI: 10.1089/cap.2009.0092

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  7 in total

Review 1.  The role of neuropsychological assessment in the functional outcomes of children with ADHD.

Authors:  Alison E Pritchard; Carly A Nigro; Lisa A Jacobson; E Mark Mahone
Journal:  Neuropsychol Rev       Date:  2011-11-15       Impact factor: 7.444

2.  ADHD & Pharmacotherapy: Past, Present and Future: A Review of the Changing Landscape of Drug Therapy for Attention Deficit Hyperactivity Disorder.

Authors:  J J Connolly; J T Glessner; J Elia; H Hakonarson
Journal:  Ther Innov Regul Sci       Date:  2015-09       Impact factor: 1.778

3.  Incremental validity of neuropsychological assessment in the identification and treatment of youth with ADHD.

Authors:  Alison E Pritchard; Taylor Koriakin; Lisa A Jacobson; E Mark Mahone
Journal:  Clin Neuropsychol       Date:  2013-12-17       Impact factor: 3.535

4.  Relationship between quality of life and psychopathological profile: data from an observational study in children with ADHD.

Authors:  Andreas Becker; Veit Roessner; Dieter Breuer; Manfred Döpfner; Aribert Rothenberger
Journal:  Eur Child Adolesc Psychiatry       Date:  2011-10       Impact factor: 4.785

5.  An observational study of once-daily modified-release methylphenidate in ADHD: quality of life, satisfaction with treatment and adherence.

Authors:  Aribert Rothenberger; Andreas Becker; Dieter Breuer; Manfred Döpfner
Journal:  Eur Child Adolesc Psychiatry       Date:  2011-10       Impact factor: 4.785

Review 6.  Transdermal therapy for attention-deficit hyperactivity disorder with the methylphenidate patch (MTS).

Authors:  Robert L Findling; Steven Dinh
Journal:  CNS Drugs       Date:  2014-03       Impact factor: 5.749

7.  Prognostic factors of improvement in health-related quality of life in atomoxetine-treated children and adolescents with attention-deficit/hyperactivity disorder, based on a pooled analysis.

Authors:  Alonso Montoya; Deborah Quail; Ernie Anand; Esther Cardo; José A Alda; Rodrigo Escobar
Journal:  Atten Defic Hyperact Disord       Date:  2013-10-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.